Panel: Cell & Gene Therapy: Bridging Innovation and Commercial Reality

Cell and gene therapies have demonstrated transformative clinical impact and are now entering a more advanced phase of commercialisation. However, scaling these therapies in a consistent, cost-effective, and globally accessible way remains a significant challenge. Despite continued innovation, progress is constrained by fragmented supply chains, complex manufacturing models, and ongoing questions around the sustainability of R&D investment.

Key discussion points:

How companies are adapting R&D and process development to support scalable, reproducible manufacturing

Whether current CGT supply chain models can support scale, or if a fundamental redesign is needed

What realistic pathways exist to reduce cost and complexity while maintaining quality

How investor expectations are evolving as CGT moves beyond early-stage innovation

The role of partnerships across biotech, CDMOs, and providers in enabling scale and access